Efficacy and tolerance of HCV treatment in HIV-HCV coinfected patients: The potential interaction of PI treatment

HIV Clinical Trials

Volumn 4, Issue 4, 2003, Pages 262-268

  Poizot Martin, I ^a,b   Marimoutou, C ^a,b   Benhaim, S ^a   Drogoul Vey, M P ^a   Dinh, T ^a   Vion Dury, F ^a   Frixon Marin, V ^a   Tamalet, C ^c   Gastaut, J A ^a,d  

^a HÔPITAL SAINTE MARGUERITE   (France)

^b INSERM   (France)

^c TIMONE HOSPITAL   (France)

^d INSTITUT PAOLI CALMETTES   (France)

Author keywords

Efficacy; HCV genotype; HCV therapy; HIV HCV coinfection; PI; Tolerance

Indexed keywords

ALPHA2B INTERFERON; POLYETHYLENE GLYCOL INTERFERON ALFA 2B; POLYETHYLENE GLYCOL-INTERFERON ALFA-2B; PROTEINASE INHIBITOR; RIBAVIRIN; UNCLASSIFIED DRUG; VIRUS RNA;

ADULT; ANEMIA; ANTIVIRAL ACTIVITY; ARTICLE; ASTHENIA; CLINICAL PROTOCOL; CLINICAL TRIAL; COMORBIDITY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG EFFECT; DRUG EFFICACY; DRUG INTERACTION; DRUG RESISTANCE; DRUG TOLERABILITY; FEMALE; FOLLOW UP; GENETICS; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RECURRENT DISEASE; RELAPSE; TOXIC HEPATITIS; VIROLOGY;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG INTERACTIONS; FEMALE; FOLLOW-UP STUDIES; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; MALE; POLYETHYLENE GLYCOLS; RECURRENCE; RIBAVIRIN;

EID: 0042566139     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/50JB-VNBB-7HRG-7GUR     Document Type: Article

References (31)

1. Di Martino V, Rufat P, Boyer N, et al. The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: a long-term retrospective cohort study. Hepatology. 2001;34:1193-1199.
2. Pol S, Fontaine H, Carnot F, et al. Predictive factors for development of cirrhosis in parenterally acquired chronic hepatitis C: a comparison between immunocompetent and immunocompromised patients. J Hepatol. 1998;29:12-19.
3. Poynard T, Leroy V, Cohard M, et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology. 1996;24:778-789.
4. Soto B, Sanchez-Quijano A, Rodrigo L, et al. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol. 1997;26:1-5.
5. Garcia-Samaniego J, Rodriguez M, Berenguer J, et al. Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C. Am J Gastroenterol. 2001;96:179-183.
6. Poles MA, Dieterich DT. Hepatitis C virus/human Immunodeficiency virus coinfection: clinical management issues. Clin Infect Dis. 2000;31:154-161.
7. Soriano V, Garcia-Samaniego J, Rodriguez-Rosado R, Gonzalez J, Pedreira J. Hepatitis C and HIV infection: biological, clinical, and therapeutic implications. J Hepatol. 1999;31 (suppl1):199-123.
8. Puoti M, Spinetti A, Ghezzi A, et al. Mortality for liver disease in patients with HIV infection: a cohort study. J Acquir Immune Defic Syndr. 2000;24:211-217.
9. Darby SC, Ewart DW, Giangrande PL, et al. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. Lancet. 1997;350:1425-1431.
10. Sulkowski MS, Mast EE, Seeff LB, Thomas DL. Hepatitis C virus infection as an opportunistic disease in persons infected with human immunodeficiency virus. Clin Infect Dis. 2000;30:S77-84.
11. Nunez M, Lana R, Mendoza JL, Martin-Carbonero L, Soriano V. Risk for severe hepatic injury after introduction of Highly Active Antiretroviral Therapy. J Acquir Immune Defic Syndr. 2001;27:426-431.
12. Saves M, Vandentorren S, Daucourt V, et al. Severe hepatic cytolysis: incidence and risk factors in patients treated by antiretroviral combinations. Aquitaine Cohort, 1996-1998. AIDS. 1999;13:F115-121.
13. Pol S. Management of hepatitis C viral infection in HIV-positive patients taking antiretroviral treatment. Presse Med. 2001;30:677-682.
14. Expert group. Coinfection par le VIH et le VHC. In: Delfraissy J, ed. Prise en charge thérapeutique des personnes infectées par le VIH. Recommandations du groupe d'experts. Paris: Médecine-Sciences/Flammarion; 2000:77-80.
15. Dodig M, Tavill AS. Hepatitis C and human immunodeficiency virus coinfections. J Clin Gastroenterol. 2001;33:367-374.
16. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. New Engl J Med. 2002;347:975-982.
17. Mc Hutchison JG, Gordon SC, Schiff ER, et al. Interferon alpha-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. New Engl J Med. 1998;339:1485-1492.
18. Reichard O, Norkrans G, Fryden A, Braconier JH, Sonnerborg A, Weiland O. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group. Lancet. 1998;351:83-87.
19. Landau A, Batisse D, Piketty C, et al. Long-term efficacy of combination therapy with interferon-alpha 2b and ribavirin for severe chronic hepatitis C in HIV-infected patients. AIDS. 2001;15:2149-2155.
20. Nasti G, Di Gennaro G, Tavio M, et al. Chronic hepatitis C in HIV infection: feasibility and sustained efficacy of therapy with interferon alfa-2b and ribavirin. AIDS. 2001;15:1783-1787.
21. Marcellin P. Hepatitis C: the clinical spectrum of the disease. J Hepatol. 1999;31(suppl1):9-16.
22. Thélot B, Pialoux G, Delhommeau A, Piroth L, Salmon-Céron D, APPIT. Epidémiologie hospitalière des patients coinfectés par le VIH et le VHC. Bull Epidemiol Hebd. 2000;(39):1-5.
23. Consensus Panel. EASL International Consensus Conference on Hepatitis C: consensus statement. J Hepatol. 1999;31(suppl1):3-8.
24. Goebel FD, Jablonowski H. Therapy of special HIV-associated diseases: HCV-HIV-co-infection and AIDS-related Kaposi's sarcoma. Eur J Med Res. 1999;4:507-513.
25. Simmonds P. Viral heterogeneity of the hepatitis C virus. J Hepatol. 1999;31(suppl 1):54-60.
26. Mondelli MU, Silini E. Clinical significance of hepatitis C virus genotype. J Hepatol. 1999;31(suppl 1):65-70.
27. Fernandez I, Rubio R, Lumbreras C. Hepatitis C in HIV-infected patients-therapeutic approach. Clin Microbiol Infect. 2002;8:80-84.
28. Benhamou Y, Di Martino V, Bochet M, et al. Factors affecting liver fibrosis in human immunodeficiency virus- and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy. Hepatology. 2001;34:283-287.
29. Trimoulet P, Neau D, Le Bail B, et al. Intrahepatic HCV RNA loads in 37 HIV-HCV co-infected patients with controlled HIV infection. J Med Virol. 2002;67:146-151.
30. Soriano V, Rodriguez-Rosado R, Garcia-Samaniego J. Management of chronic hepatitis C in HIV-Infected patients. AIDS. 1999;13:539-546.
31. Poynard T, McHutchison J, Manns M, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology. 2002;122:1303-1313.